Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed
Rhea-AI Filing Summary
Neurogene Inc. President and CFO Christine Mikail Cvijic reported automatic sales of common stock tied to a restricted stock unit (RSU) vesting. On March 13, 2026, a total of 4,045 shares of Neurogene common stock were sold in three open-market transactions at weighted average prices of $20.4224, $21.2451, and $22.0195 per share.
According to the disclosure, these sales were executed under the RSU award agreement, which requires the company to sell enough shares to cover the executive’s tax withholding obligations from the March 12, 2025 vesting event, with no election by the executive. After the sales, Cvijic directly owned 105,798 common shares, in addition to multiple unvested RSU awards scheduled to vest between 2026 and 2029.
Positive
- None.
Negative
- None.
Insights
Small, tax-driven insider sale linked to RSU vesting; routine event.
The transactions involve 4,045 Neurogene common shares sold by President and CFO Christine Mikail Cvijic on March 13, 2026. All are coded as open-market sales at weighted average prices between $19.92 and $22.075 per share.
A key footnote states the RSU award agreement obligates the company to sell enough shares to cover her tax withholding from a March 12, 2025 vesting, with no election by her. That makes this a mechanistic, tax-driven sale rather than a discretionary portfolio move.
After these sales, she directly holds 105,798 shares plus several unvested RSU grants scheduled to vest from 2026 through 2029. Given the modest size relative to her remaining position and the mandatory nature, this looks like a routine compensation-related transaction with limited signaling value.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,387 | $20.4224 | $49K |
| Sale | Common Stock | 1,395 | $21.2451 | $30K |
| Sale | Common Stock | 263 | $22.0195 | $6K |
Footnotes (1)
- On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
